UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, announced that the independent Data Monitoring Committee (DMC) for the Phase 1/2/3 LIGHTHOUSE Trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS) has completed its review of accumulated data from Parts A and B of the study and has recommended that the Company proceed with enrollment of the pivotal Part C cohort. Atsena will initiate Part C screening this month.
“We are excited that the DMC has recommended that we proceed with the pivotal Part C cohort,” said Kenji Fujita, MD, Chief Medical Officer of Atsena Therapeutics. “This recommendation reflects the strength of the safety and efficacy data we have accumulated to date and brings us one step closer to delivering what we believe will be the first approved therapy for patients with XLRS.”
